Nevro (NVRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a chan ...

Nevro Corp. (NVRO) recently announced the publication of new data in the journal, Medical Devices: Evidence and Research, demonstrating the superiority of the Nevro1 sacroiliac (SI) Joint Fusion System (Nevro1).Nevro1 is a posterior integrated transfixation cage system that offers enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. Nevro1's performance also demonstrated that it is equivalent in osteopenic bone com ...

Furthering Nevro's body of evidence as an innovation leader in pain management, data highlights the company's posterior integrated transfixation cage systemREDWOOD CITY, Calif., Nov. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1™ SI Joint Fusion S ...

Nevro Corp. (NVRO) recently received CE Mark Certification in Europe for its HFX iQ spinal cord stimulation (SCS) system.  The company can now market HFX iQ in all countries that recognize this certification. Nevro plans to launch the HFX iQ system in select European countries starting first-quarter 2025.With the latest CE Mark Certification for HFX iQ, Nevro marks a milestone in its strategic journey to drive market penetration through data-backed, AI-powered SCS therapy.Likely Trend of NVRO Stock Followin ...

Exhibit 99.1 Nevro Reports Third-Quarter 2024 Financial Results Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, California – November 11, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidanc ...

Nevro Corp. (NVRO) reported a loss per share of 41 cents in the third quarter of 2024, narrower than the year-ago quarter’s loss of 65 cents. The Zacks Consensus Estimate is pegged at a loss per share of 82 cents.Revenues in DetailNevro registered worldwide revenues of $96.9 million in the third quarter, down 6.7% year over year on a reported basis and 7% on a constant-currency basis. The year-over-year decline was primarily due to competitive pressures in the U.S. spinal cord stimulation (SCS) market and o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) ( ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care*REDWOOD CITY, Calif., Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation ...

IIIIIII nevice Third Quarter 2024 Earnings Conference Call November 11, 2024 ©2024 Nevro Corp. All rights reserved. S000000 Forward-Looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the current beliefs and expectations of the company's management, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our full-year 2024 financial guidance; our belief that the actions we have take ...

Nevro Corp. (NYSE:NVRO) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Shagun Singh - RBC Capital Markets Robbie Marcus - JPMorgan Matt Taylor - Jefferies Brandon Vazquez - William Blair Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Richard ...